Researchers at The University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib.
The findings, published in the Feb. 14 edition of The Lancet Oncology, show that selumetinib targets a mutation in the MAPK pathway for patients with low-grade serous carcinoma, allowing for treatment on previously chemoresistant tumors.
"This is a potentially important breakthrough for the Gynecologic Oncology Group," said John Farley, MD, a gynecologic oncologist in the Division of Gynecologic Oncology and the Department of Obstetrics and Gynecology at the Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, a Dignity Health Member.
The Gynecologic Oncology Group is a non-profit international organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies.
Dr. Farley is part of the University of Arizona Cancer Center at St. Joseph's and is board certified in obstetrics and gynecology with a subspecialty certification in gynecologic oncology. He is a retired decorated Army colonel who completed a residency in obstetrics and gynecology and a fellowship in gynecologic oncology at Walter Reed Army Medical Center. He is the first author on this study.
This study was initially developed in 2007, with 52 patients enrolled for the Phase II clinical trial between December 2007 and November 2009. Patients were given 50 milligrams of selumetinib orally twice daily. Of those participants, eight had a measurable decrease in tumor size, seven had partial responses and 34 patients saw their tumors stabilize. The findings suggest that inhibitors of the MAPK pathway warrant further investigation in patients with low-grade ovarian cancer.
"There just aren't very good treatments for low-grade ovarian cancer, so this discovery opens up a lot of new exciting possibilities for us," Dr. Farley said. He added that Phase III of this trial is scheduled to begin in the next few weeks, with that trial to be the "definitive test" before the treatment becomes available to the general population.
This study is registered with ClinicalTrials.gov, number NCT00551070.
About The University of Arizona Cancer Center
The University of Arizona Cancer Center is the only National Cancer Institute-designated Comprehensive Cancer Center headquartered in Arizona. The UACC is supported by NCI Cancer Center Support Grant number CA023074. With primary locations at the University of Arizona in Tucson and at St. Joseph's Hospital and Medical Center in Phoenix, the Cancer Center has more than a dozen research and education offices in Phoenix and throughout the state and 300 physician and scientist members work together to prevent and cure cancer. For more information, go to http://www.arizonacancercenter.org
About St. Joseph's Hospital and Medical Center
Located in the heart of Phoenix, Ariz., St. Joseph's Hospital and Medical Center is a 607-bed, not-for-profit hospital that provides a wide range of health, social and support services with special advocacy for the poor and underserved. St. Joseph's is a nationally recognized center for quality tertiary care, medical education and research. It includes the internationally renowned Barrow Neurological Institute, the Heart & Lung Institute, the Muhammad Ali Parkinson Center, and a Level I Trauma Center verified by the American College of Surgeons. U.S. News & World Report routinely ranks St. Joseph's among the best hospitals in the United States for neurology and neurosurgery.
More articles from Health and Medicine:
Study shows that insomnia may cause dysfunction in emotional brain circuitry
23.05.2013 | American Academy of Sleep Medicine
Changing cancer's environment to halt its spread
22.05.2013 | Boston Children's Hospital
New indicator molecules visualise the activation of auto-aggressive T cells in the body as never before
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to examine individual cells and their activity directly in the tissue.
The development of new microscopes and fluorescent dyes in ...
A fried breakfast food popular in Spain provided the inspiration for the development of doughnut-shaped droplets that may provide scientists with a new approach for studying fundamental issues in physics, mathematics and materials.
The doughnut-shaped droplets, a shape known as toroidal, are formed from two dissimilar liquids using a simple rotating stage and an injection needle. About a millimeter in overall size, the droplets are produced individually, their shapes maintained by a surrounding springy material made of polymers.
Droplets in this toroidal shape made ...
Frauhofer FEP will present a novel roll-to-roll manufacturing process for high-barriers and functional films for flexible displays at the SID DisplayWeek 2013 in Vancouver – the International showcase for the Display Industry.
Displays that are flexible and paper thin at the same time?! What might still seem like science fiction will be a major topic at the SID Display Week 2013 that currently takes place in Vancouver in Canada.
High manufacturing cost and a short lifetime are still a major obstacle on ...
University of Würzburg physicists have succeeded in creating a new type of laser.
Its operation principle is completely different from conventional devices, which opens up the possibility of a significantly reduced energy input requirement. The researchers report their work in the current issue of Nature.
It also emits light the waves of which are in phase with one another: the polariton laser, developed ...
Innsbruck physicists led by Rainer Blatt and Peter Zoller experimentally gained a deep insight into the nature of quantum mechanical phase transitions.
They are the first scientists that simulated the competition between two rival dynamical processes at a novel type of transition between two quantum mechanical orders. They have published the results of their work in the journal Nature Physics.
“When water boils, its molecules are released as vapor. We call this ...
23.05.2013 | Physics and Astronomy
23.05.2013 | Health and Medicine
23.05.2013 | Ecology, The Environment and Conservation
17.05.2013 | Event News
15.05.2013 | Event News
08.05.2013 | Event News